Immedica Pharma AB is pleased to announce that the UK MHRA has approved Efmody (modified-release hydrocortisone) for the treatment of adrenal insufficiency in adolescents aged 12 years and… read more.
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a… read more.
MannKind Corporation announced that the FDA has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and… read more.
Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual… read more.
Novo Nordisk presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS clinical trials at the 2026 Scientific Sessions of the American Diabetes Association (ADA), highlighting data regarding the impact… read more.
Abbott announced it has secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day,… read more.
An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June… read more.
Researchers report that early treatment of type 2 diabetes with tirzepatide leads to greater improvements over 2 years in blood sugar, body weight, and waist size than treatment… read more.
The FDA has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age… read more.
A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years. The… read more.
A healthy diet, weight loss, and increased physical activity can effectively prevent type 2 diabetes. However, not all individuals at elevated diabetes risk benefit equally from lifestyle interventions…. read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Kyinsu (insulin icodec + semaglutide, IcoSema) intended… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
